The incidence of cervical cancer ranks fourth in the world for female malignancies, and it is the main cause of cancer deaths among women in developing countries. In some areas where the economy and culture are relatively backward, the awareness and implementation rate of "step screening for cervical cancer" are poor, so that more than 1/3 patients are at stage ⅠB3 (FIGO stage in 2018) and above of the cervical cancer when they found it, and lost the best time for operation. The concept of neoadjuvant chemotherapy (NACT) before operation, which is in order to shrink tumors and eliminate micrometastases, has been widely accepted in many tumor species. It also has been practiced a lot in the treatment of cervical cancer in China. However, the concrete proposal of NACT for cervical cancer has not been unified yet. Paclitaxel is a commonly used drug in the chemotherapy of cervical cancer, which is highly toxic and poorly tolerated by patients. The nanoparticle albumin bound paclitaxel (Nab-paclitaxel), a small molecule nanoparticle which uses human serum albumin as the solvent, is poorly toxicity and highly efficiency. As a new formulation of paclitaxel, it is widely used. Now, this article summarizes the principles, the efficacy, adverse reactions and long-term application of Nab-paclitaxel and traditional solvent-based paclitaxel in NACT for cervical cancer.
